Related Experiment Videos
[Pharmacokinetics and clinical effects of aspoxicillin in pediatric patients]
Insights
Aspoxicillin (ASPC) demonstrated high efficacy and safety in pediatric patients, achieving a 90.6% cure rate across various infections. This study confirms ASPC
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology and Therapeutics
- Clinical Microbiology
Context:
- The established efficacy and safety of aspoxicillin (ASPC) in adults necessitated evaluating its use in pediatric populations.
- Pediatric infections pose unique challenges requiring tailored therapeutic options.
Purpose:
- To assess the clinical utility, pharmacokinetic profile, and bacteriological effects of aspoxicillin (ASPC) in pediatric patients.
- To determine the safety and effectiveness of ASPC in treating diverse infections in children.
Summary:
- A multi-center study involving 318 pediatric patients evaluated aspoxicillin (ASPC) pharmacokinetics and clinical outcomes.
- ASPC showed significant effectiveness, with an overall cure rate of 90.6%, eradicating pathogens in 88.3% of cases.
- The drug was effective in serious infections (93.3%) and in patients with underlying conditions (79.2%), though outcomes differed significantly between these groups.
Impact:
- This research supports aspoxicillin (ASPC) as a valuable therapeutic option for pediatric infections.
- The findings provide crucial data for the expanded use of ASPC in pediatric clinical practice.
- Establishes a foundation for further research into ASPC's role in pediatric infectious disease management.
Abstract:
Since the efficacy and the safety of aspoxicillin (ASPC, TA-058) have been established on adult patients and the need of ASPC use on pediatric patients was anticipated, we performed a 16 center study on the clinical utility of ASPC in pediatric patients. 1. Pharmacokinetics ASPC was intravenously administered to 45 patients at a dose of 10, 20 or 40 mg/kg by one shot. Serum concentrations of ASPC were dependent of dose levels, and maximum levels of 58.4-230.8 micrograms/ml and half-lives (beta) of 1.08-1.16 hours were observed. Urinary recovery rates were 62.7-67.2% in 6 hours. Results obtained upon drip infusions (0.5-1 hour) were similar to one shot injections. 2. Clinical results (1) Clinical effectiveness Of 318 evaluable patients including 175 boys and 143 girls, 18.2% were nurslings and 61% were young children under 4 years of age. One hundred eighty six patients from whom causative organisms were isolated were classified as A group. Among them were 5 patients suffered with sepsis, but the ASPC treatment eradicated all the bacteria but Salmonella java in 1 case. All of 4 patients with meningitis were cured and all causative organisms (3 cases with Haemophilus influenzae and 1 case with Gram-positive coccus) were eradicated. Cure rates were 90% for 130 patients with respiratory tract infection, 88.6% for 35 with urinary tract infection, 85.7% for 7 with skin soft tissue infection and 89.8% for all the A group patients. Meanwhile, no causative organisms were isolated from 132 patients (B group patients) but cure rate of 91.7% was obtained for this group. No statistical difference was observed between A and B groups. For all the patients (318), the cure rate was 90.6%. (2) Bacteriological effects Of 63 Gram-positive bacteria isolated as pathogens, 58 strains were eradicated. Of 117 Gram-negative bacterial, 101 were eradicated. The eradication rate on all 180 strains was 88.3%. Overall, ASPC showed excellent effects against Streptococcus. Among strains of Staphylococcus aureus, 18 of 20 strains were eradicated. Of 59 strains of H. influenzae, 52 were eradicated and 3 decreased. Among strains of Escherichia coli, 25 of 28 strains were eradicated. Of Pseudomonas aeruginosa, 2 strains were decreased and one was unchanged. (3) ASPC was effective in 93.3% of 30 patients with serious infections and 79.2% of 72 patients with underlying diseases. Cure rates for patients with and without underlying disease were significantly different statistically (chi 2: P less than 0.005).(ABSTRACT TRUNCATED AT 400 WORDS)